Replies to post #113841 on Biotech Values

[DewDiligence]

I rank PFE behind NVS and ABT (#msg-51791410), but I think all three are strong buys at the current valuations.

[Dub Narcotic]

In the same vein, I'm sure I'm not the only one looking forward to the NY Times expose and congressional hearings into CRO business and clinical practices in five to seven years. Well, Ian Read will be long gone, counting his option and bonus money, before those chickens come home to roost.